Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Jones RH, Fizazi K, James ND, Tammela TL, Matsubara N, Priou F, Beuzeboc P, Lesimple T, Bono P, Kataja V, Garcia JA, Protheroe A, Shore N, Aspegren J, Joensuu H, Kuss I, Fiala-Buskies S, Vjaters E.
Jones RH, et al. Among authors: kataja v.
Prostate Cancer Prostatic Dis. 2023 Oct 26. doi: 10.1038/s41391-023-00740-9. Online ahead of print.
Prostate Cancer Prostatic Dis. 2023.
PMID: 37884613